Effect of CCL5 expression in the recruitment of immune cells in triple negative breast cancer
Open accessAbstract
Triple negative breast cancer (TNBC) is the most aggressive form of breast cancer with limited options of targeted therapy. Recent findings suggest that the clinical course of TNBC may be modified by the presence of tumor-infiltrating lymphocytes (TILs) and chemokine’s expression, such as CCL5 . Diverse studies have shown that CCL5 suppresses anti-tumor immunity and it has been related to poor outcome in different types of cancer while in other studies, this gene has been related with a better outcome. We sought to determine the association of CCL5 with the recruitment of TILs and other immune cells. With this aim we evaluated a retrospective cohort of 72 TNBC patients as well as publicly available datasets. TILs were correlated with residual tumor size after neoadjuvant chemotherapy (NAC) and CCL5 expression. In univariate analysis, TILs and CCL5 were both associated to the distant recurrence free survival; however, in a multivariate analysis, TILs was the only significant marker (HR = 0.336; 95%IC: 0.150–0.753; P = 0.008). CIBERSORT analysis suggested that a high CCL5 expression was associated with recruitment of CD8 T cells, CD4 activated T cells, NK activated cells and macrophages M1. The CD8A gene (encoding for CD8) was associated with an improved outcome in several public breast cancer datasets.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
SHP099 and G12C-I each increased the expression of chemokine and cytokine genes that promote T cell recruitment (e.g., CXCL9-11; CCL5).
“SHP099 and G12C-I each increased the expression of chemokine and cytokine genes that promote T cell recruitment (e.g., CXCL9-11; CCL5; Araujo et al., 2018; Chow and Luster, 2014; Lavergne et al., 2004; Nagarsheth et al., 2017; Tokunaga et al., 2018)”
From SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling (2021) · cites this paper as Araujo et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455 · see citing works
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160 · see citing works
Robust enumeration of cell subsets from tissue expression profiles
Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., Hoang, C. D., Diehn, M., & Alizadeh, A. A. (2015) · Nature Methods · doi:10.1038/nmeth.3337 · Cited by 12,116 · see citing works
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592 · see citing works
Györffy, B., Lanczky, A., Eklund, A. C., Denkert, C., Budczies, J., Li, Q., & Szallasi, Z. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0674-9 · Cited by 4,169 · see citing works
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., Richardson, A. L., Polyak, K., Tubo, R., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06188 · Cited by 3,206 · see citing works
The prognostic landscape of genes and infiltrating immune cells across human cancers
Gentles, A. J., Newman, A. M., Liu, C. L., Bratman, S. V., Feng, W., Kim, D., Nair, V. S., Xu, Y., Khuong, A., Hoang, C. D., et al. (2015) · Nature Medicine · doi:10.1038/nm.3909 · Cited by 3,097 · see citing works
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
Fisher, B., Bryant, J., Wolmark, N., Mamounas, E. P., Brown, A., Fisher, E. R., Wickerham, D. L., Begovič, M., DeCillis, A. P., Robidoux, A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2672 · Cited by 2,164 · see citing works
Denkert, C., Loibl, S., Noske, A., Roller, M., Müller, B. M., Komor, M., Budczies, J., Darb‐Esfahani, S., Kronenwett, R., Hanusch, C. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7370 · Cited by 1,751 · see citing works
Adams, S., Gray, R. J., Demaria, S., Goldstein, L. J., Perez, E. A., Shulman, L. N., Martino, S., Wang, M., Jones, V. E., Saphner, T. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.55.0491 · Cited by 1,301 · see citing works
Loi, S., Michiels, S., Salgado, R., Sirtaine, N., José, V., Fumagalli, D., Kellokumpu‐Lehtinen, P., Bono, P., Kataja, V. V., Desmedt, C., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu112 · Cited by 1,257 · see citing works
Self-citationDenkert, C., von Minckwitz, G., Brase, J. C., Sinn, B. V., Gade, S., Kronenwett, R., Pfitzner, B. M., Salat, C., Loi, S., Schmitt, W., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.1967 · Cited by 1,026 · see citing works
Neoadjuvant Chemotherapy in Breast Cancer: Significantly Enhanced Response With Docetaxel
Smith, I. C. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1456 · Cited by 713 · see citing works
Loi, S., Dushyanthen, S., Beavis, P. A., Salgado, R., Denkert, C., Savas, P., Combs, S., Rimm, D. L., Giltnane, J. M., Estrada, M. V., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1125 · Cited by 536 · see citing works
Self-citationAli, H. R., Chlon, L., Pharoah, P., Markowetz, F., & Caldas, C. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002194 · Cited by 523 · see citing works
Balko, J. M., Giltnane, J. M., Wang, K., Schwarz, L. J., Young, C. D., Cook, R. S., Owens, P., Sanders, M. E., Kuba, M. G., Sanchez, V. M., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0286 · Cited by 488 · see citing works
Self-citationDieci, M. V., Criscitiello, C., Goubar, A., Viale, G., Conte, P., Guarneri, V., Ficarra, G., Mathieu, M. C., Delaloge, S., Curigliano, G., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt556 · Cited by 457 · see citing works
Neoadjuvant Chemotherapy in Breast Cancer: Significantly Enhanced Response With Docetaxel
Smith, I. C., Heys, S. D., Hutcheon, A. W., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.6.1456 · Cited by 448 · see citing works
deLeeuw, R., Kost, S., Kakal, J., & Nelson, B. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3216 · Cited by 444 · see citing works
Dieci, M. V., Radosevic‐Robin, N., Fineberg, S., den Eynden, G. V., Ternès, N., Penault-Llorca, F. M., Pruneri, G., D’Alfonso, T. M., Demaria, S., Castañeda, C. A., et al. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.10.003 · Cited by 431 · see citing works
Self-citationChew, V., Chen, J., Lee, D., Loh, E., Lee, J., Lim, K. H., Weber, A., Slankamenac, K., Poon, R. T. P., Yang, H. H., et al. (2011) · Gut · doi:10.1136/gutjnl-2011-300509 · Cited by 360 · see citing works
West, N. R., Milne, K., Truong, P. T., Macpherson, N. A., Nelson, B. H., & Watson, P. H. (2011) · Breast Cancer Research · doi:10.1186/bcr3072 · Cited by 355 · see citing works
CCR5 Antagonist Blocks Metastasis of Basal Breast Cancer Cells
Velasco-Velázquez, M. A., Jiao, X., Fuente, M. D. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3917 · Cited by 282 · see citing works
West, N. R., Kost, S. E., Martin, S. D., Milne, K., deLeeuw, R. J., Nelson, B. H., & Watson, P. H. (2013) · British Journal of Cancer · doi:10.1038/bjc.2012.524 · Cited by 268 · see citing works
Balko, J. M., Cook, R. S., Vaught, D. B., Kuba, M. G., Miller, T. W., Bhola, N. E., Sanders, M. E., Granja-Ingram, N. M., Smith, J. J., Meszoely, I. M., et al. (2012) · Nature Medicine · doi:10.1038/nm.2795 · Cited by 262 · see citing works
Identification of high-quality cancer prognostic markers and metastasis network modules
Li, J., Lenferink, A. E. G., Deng, Y., Collins, C., Cui, Q., Purisima, E. O., O'Connor‐McCourt, M. D., & Wang, E. (2010) · Nature Communications · doi:10.1038/ncomms1033 · Cited by 258 · see citing works
Ibrahim, E. M., Al‐Foheidi, M., Al-Mansour, M. M., & Kazkaz, G. A. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3185-2 · Cited by 245 · see citing works
Cancer-FOXP3 directly activated CCL5 to recruit FOXP3+Treg cells in pancreatic ductal adenocarcinoma
Wang, X., Lang, M., Zhao, T., Feng, X., Zheng, C., Huang, C., Hao, J., Dong, J., Luo, L., Li, X., et al. (2016) · Oncogene · doi:10.1038/onc.2016.458 · Cited by 228 · see citing works
Issa-Nummer, Y., Darb‐Esfahani, S., Loibl, S., Kunz, G., Nekljudova, V., Schrader, I., Sinn, B. V., Ulmer, H.-U., Kronenwett, R., Just, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079775 · Cited by 223 · see citing works
Stagg, J., & Allard, B. (2013) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834012475152 · Cited by 165 · see citing works
Yaal‐Hahoshen, N., Shina, S., Leider–Trejo, L., Barnea, I., Shabtai, E. L., Azenshtein, E., Greenberg, I., Keydar, I., & Ben‐Baruch, A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0074 · Cited by 150 · see citing works
Yamaguchi, R., Tanaka, M., Yano, A., Tse, G. M.-K., Yamaguchi, M., Koura, K., Kanomata, N., Kawaguchi, A., Akiba, J., Naito, Y., et al. (2012) · Human Pathology · doi:10.1016/j.humpath.2011.12.013 · Cited by 147 · see citing works
D’Esposito, V., Liguoro, D., Ambrosio, M. R., Collina, F., Cantile, M., Spinelli, R., Raciti, G. A., Miele, C., Valentino, R., Campiglia, P., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8336 · Cited by 146 · see citing works
Liu, J., Li, F., Yü, P., Wang, L., Chen, X., Wang, D., Cao, L., Zhao, S. Q., Li, B., Kaliński, P., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4617 · Cited by 118 · see citing works
Zhang, Y., Lv, D., Kim, H.-J., Kurt, R. A., Bu, W., Li, Y., & Ma, X. (2012) · Cell Research · doi:10.1038/cr.2012.178 · Cited by 118 · see citing works
Sugasawa, H., Ichikura, T., Kinoshita, M., Ono, S., Majima, T., Tsujimoto, H., Chochi, K., Hiroi, S., Takayama, E., Saitoh, D., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23401 · Cited by 74 · see citing works
The CCL5/CCR5 axis promotes metastasis in basal breast cancer
Velasco-Velázquez, M. A., & Pestell, R. G. (2013) · OncoImmunology · doi:10.4161/onci.23660 · Cited by 73 · see citing works
Lee, H. J., Lee, J.-J., Song, I. H., Park, I. A., Kang, J. K., Yu, J. H., Ahn, J., & Gong, G. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3438-8 · Cited by 71 · see citing works
Wang, X., Yang, X., Tsai, Y., Li, Y., Chuang, K., Keng, P. C., Lee, S. O., & Chen, Y. (2017) · Radiation Research · doi:10.1667/rr14503.1 · Cited by 65 · see citing works
Fertig, E. J., Lee, E., Pandey, N. B., & Popel, A. S. (2015) · Scientific Reports · doi:10.1038/srep12133 · Cited by 54 · see citing works
Kawazu, M., Kojima, S., Ueno, T., Totoki, Y., Nakamura, H. K., Kunita, A., Qü, W., Yoshimura, J., Soda, M., Yasuda, T., et al. (2017) · PLoS Genetics · doi:10.1371/journal.pgen.1006853 · Cited by 48 · see citing works
Pinto, J. A., Araujo, J. M., Cardenas, N. K., Morante, Z., Doimi, F. D., Vidaurre, T., Balko, J. M., & Gómez, H. (2016) · npj Genomic Medicine · doi:10.1038/npjgenmed.2015.15 · Cited by 40 · see citing works
Self-citationLoi, S., Drubay, D., Adams, S., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.sabcs15-s1-03 · Cited by 35 · see citing works
Uehara, J., Ohkuri, T., Kosaka, A., Ishibashi, K., Hirata, Y., Ohara, K., Nagato, T., Oikawa, K., Aoki, N., Harabuchi, Y., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.06.072 · Cited by 22 · see citing works
Gene Regulatory Network Rewiring in the Immune Cells Associated with Cancer
Han, P., Gopalakrishnan, C., Yu, H., & Wang, E. (2017) · Genes · doi:10.3390/genes8110308 · Cited by 17 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Peripheral T cell expansion predicts tumour infiltration and clinical response
Wu, T. D., Madireddi, S., de Almeida, P. E., Banchereau, R., Chen, Y.-J. J., Chitre, A. S., Chiang, E. Y., Iftikhar, H., O’Gorman, W. E., Au-Yeung, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2056-8 · Cited by 770 · see citing works
Pantelidou, C., Sonzogni, O., De Oliveria Taveira, M., Mehta, A. K., Kothari, A., Wang, D., Visal, T., Li, M. K., Pinto, J., Castrillon, J. A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1218 · Cited by 743 · see citing works
SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling
Fedele, C., Li, S., Teng, K. W., Foster, C. J. R., Peng, D., Ran, H., Mita, P., Geer, M. J., Hattori, T., Koide, A., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201414 · Cited by 265 · see citing works
Cai, B., Lin, D., Li, Y., Wang, L., Xie, J., Dai, T., Liu, F., Tang, M., Tian, L., Yuan, Y., et al. (2021) · Advanced Science · doi:10.1002/advs.202100584 · Cited by 187 · see citing works
- Authors
- Araujo, J. M., Gomez, A. C., Aguilar, A., Salgado, R., Balko, J. M., Bravo, L., Doimi, F., Bretel, D., Morante, Z., Flores, C., Gomez, H. L., & Pinto, J. A.
- Affiliations
- Institut Jules Bordet (BE)
- Vanderbilt University (US)
- Universidad Privada San Juan Bautista (PE)
- Instituto Nacional de Enfermedades Neoplásicas (PE)
- ORCID
- Venue
- Scientific Reports
- Published
- 2018-03-20
- Volume
- 8
- Issue
- 1
- Pages
- 4899-4899
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC5861063
- OpenAlex
- W2805359975
- Cited by
- 108
- References
- 47
- Citations by year
- 2026: 12 · 2025: 14 · 2024: 10 · 2023: 14 · 2022: 12 · 2021: 21 · 2020: 10 · 2019: 13 · 2018: 2
- FWCI
- 3.48
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by)
- Greater South Information System
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- triple-negative breast cancer, RANTES, tumor-infiltrating lymphocytes, immune cell recruitment, chemokines, CD8+ T cells, natural killer cells, macrophages, neoadjuvant chemotherapy, distant recurrence-free survival, CD8A, tumor immune microenvironment
- MeSH terms
- Adult, Aged, Cell Movement, Female, Humans, Killer Cells, Natural, Macrophages, Middle Aged, Peru, Retrospective Studies, Cohort Studies, Lymphocytes, Tumor-Infiltrating, CD8 Antigens, CD8-Positive T-Lymphocytes, Disease-Free Survival, Chemokine CCL5, Neoadjuvant Therapy, Tumor Burden, Young Adult, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
